GlassScriptPhysician profile
Sahar Eftekharzadeh
NPI 1114657962
$2,673.49
in general payments reported to CMS, 2019-2025
13 companies · $893 in 2025
The $893 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $427 · 2023: $813 · 2024: $541 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,146.60 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,094.55 | 2022-2025 | Ams 700, Lithovue, Lithoclast |
| Janssen Scientific Affairs, LLC | $274.20 | 2022-2025 | Erleada |
| Urogen Pharma, INC. | $256.45 | 2023-2025 | Jelmyto |
| Coloplast Corp | $185.95 | 2025 | |
| Janssen Biotech, INC. | $173.90 | 2023-2024 | Erleada |
| Teleflex LLC | $147.78 | 2024 | Urolift |
| Astellas Pharma Global Development | $130.99 | 2022-2025 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $117.94 | 2022-2023 | |
| Medtronic, INC. | $116.28 | 2023 | Interstim |
| Photocure INC | $69.06 | 2025 | Cysview |
| Tolmar, INC. | $63.73 | 2024-2025 | Jatenzo, Eligard |
| Merck Sharp & Dohme LLC | $22.23 | 2024 | Keytruda |
| Endo USA, INC. | $20.43 | 2024 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahar Eftekharzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.